Evivar Medical Pty Ltd.
Records under this name other than patents Evivar Medical Pty Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Evivar Medical Pty Ltd.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,859,198 | Detection and Use of Antiviral Resistance Mutations Lapsed on the fee record Ended Oct 14, 2026 · High confidence | Lapsed on the fee record | Ended Oct 14, 2026 | High confidence |
| US 8,211,443 | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof Lapsed on the fee record Ended Jul 3, 2024 · USPTO record | Lapsed on the fee record | Ended Jul 3, 2024 | USPTO record |
| US 8,008,000 | Viral variants detection and application Lapsed on the fee record Ended Aug 30, 2023 · USPTO record | Lapsed on the fee record | Ended Aug 30, 2023 | USPTO record |
| US 8,211,633 | Viral variants with altered susceptibility to nucleoside analogs and uses thereof Term ended Ended no later than Feb 5, 2023 · USPTO record | Term ended | Ended no later than Feb 5, 2023 | USPTO record |
| US 7,745,130 | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof Lapsed on the fee record Ended Jun 29, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 29, 2022 | USPTO record |
| US 8,273,527 | Viral variants Term ended Term ended Mar 10, 2022 · USPTO record | Term ended | Term ended Mar 10, 2022 | USPTO record |
| US 7,431,933 | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same Term ended Term ended Nov 26, 2021 · USPTO record | Term ended | Term ended Nov 26, 2021 | USPTO record |
| US 8,592,143 | Hepatitis B viral variants with reduced susceptibility to nucleoside analogs and uses thereof Lapsed on the fee record Ended Nov 26, 2021 · USPTO record | Lapsed on the fee record | Ended Nov 26, 2021 | USPTO record |
| US 7,931,907 | Hepatitis B virus DNA polymerase and surface antigen variants and methods of using same Term ended Term ended Aug 3, 2021 · USPTO record | Term ended | Term ended Aug 3, 2021 | USPTO record |
| US 9,701,982 | Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof Lapsed on the fee record Ended Jul 11, 2021 · USPTO record | Lapsed on the fee record | Ended Jul 11, 2021 | USPTO record |